Despite the covid-19 crisis and no mega-rounds of investment in 2020, Biotech start-ups are back at the top!Swiss Biotech startups collected more than CHF 800 million in 2020, an increase of 31% compared to 2019. This is linked to the fact that innovation in drug development is taking place in the long term and, to…

We are very excited to welcome Léa Todeschini as Business Developer in our team! Léa will be responsible for the growth and development of new business while maintaining customer relationships. We are looking forward to grow and further develop our company together with Léa. If you happen to be near our office, stop by and…

Here is the team behind the scene! Big thanks to Innosuisse for their support and helping us bringing our chip one step closer to society.Check out the article: Reproducing pulmonary function in the lab Video: © Innosuisse / FDFA Presence Switzerland

Congratulations to Théo Imler for his graduation as MSc. in Life Sciences and Engineering by EPFL!Théo did an excellent defense of his MSc. Thesis project, focused on developing and characterizing a novel cellular model for modeling Vascular Leak Syndrome on the AlveoliX Lung-On-Chip.Congrats on this great achievement!

In this new work by Olivier Guenat and Thomas Geiser together with Francois Berthiaume, the possibilities of extracting clinically relevant tissue-level information from Organ on Chip devices are set into perspective. Check this enlightening work in “Clinically Relevant Tissue Scale Responses as New Readouts from Organs-on-a-Chip for Precision Medicine”. Learn more

After having completed the phase of Core Coaching, we have been successfully certified as a company “ready for sustainable growth” by Innosuisse, The Swiss Innovation Agency. We are excited about the new growth phase ahead of us.

AlveoliX  innovative contribution for lung-on-chip based inhalation assays has been published in “Advanced in vitro lung-on-chip platforms for inhalation assays: From prospect to pipeline” in collaboration with the Israel Institute of Technology, ARTORG Center and Helmholtz Institute for Pharmaceutical Research Saarland. Learn more

The Swiss Institute for Translation and Entrepreneurship in Medicine opens its doors to the public on August 30th to share the spirit of innovation and translational medicine. Join AlveoliX and all new units at SITEM, who will be exposing their cutting-edge technology to make patients life better.

In the course of this continuous growth, the Board of Directors has decided to further strengthen the positive momentum with a concentrated charge of expertise. Dr. Janick Stucki, AlveoliX’s Chief Technical Officer, and Dr. Nina Hobi, AlveoliX’s Chief Scientific Officer, have been appointed as the company’s new Co-CEOs. Stucki and Hobi succeed Prof. Olivier Guenat,…